semaglutide chronic kidney disease Notable Articles of 2024: FLOW trial In patients with type 2 diabetes and disease, weekly significantly reduced risks of major kidney events, cardiovascular events, and death from any cause Semaglutide in Diabetic Kidney Disease:

From Silicon Valley execs to busy moms and everyday professionals, millions are turning to GLP-1 treatments to lose weight safely, improve energy, and regain control over their health

About obesity Obesity is a serious chronic, progressive, and misunderstood disease that requires long-term management

While the medication does not directly cause muscle weakness through a neuromuscular mechanism, the combination of fatigue, gastrointestinal symptoms, rapid weight loss, and dietary changes associated with semaglutide therapy creates a clinical context where weakness can reasonably occur as a secondary phenomenon

Francavilla S, et al

Hands down, the scariest feeling I've ever had